@POWERbreatheUK https://t.co/R3v3drIfRF This is the paper quoted by @TrudellMed
RT @JudySchloss: @jo_pentland @LauraGroom01 @susie_mullen Better outcomes with Aerobika for #COPD & #chronicbronchitis patients. I prefer A…
@jo_pentland @LauraGroom01 @susie_mullen Better outcomes with Aerobika for #COPD & #chronicbronchitis patients. I prefer Aerobika - easier to use and it can be cleaned and used for 1yr https://t.co/tZFXhfx1sk
RT @apl104: Compared to Acapella users, Aerobika device users had 17% fewer severe exacerbations (estimate 0.83;95% CI, 0.71–0.96) and had…
RT @apl104: Compared to Acapella users, Aerobika device users had 17% fewer severe exacerbations (estimate 0.83;95% CI, 0.71–0.96) and had…
There’s a new study showing decrease exacerbations and readmissions at 30 days and 12 month for #COPD or #chronicbronchitis patients using this!! https://t.co/jvhfquzu5C
RT @apl104: Compared to Acapella users, Aerobika device users had 17% fewer severe exacerbations (estimate 0.83;95% CI, 0.71–0.96) and had…
Compared to Acapella users, Aerobika device users had 17% fewer severe exacerbations (estimate 0.83;95% CI, 0.71–0.96) and had 20% lower odds of 12-month severe disease exacerbation (OR 0.80; 95% CI, 0.66–0.98) #COPD Read funding and disclosures https://